As the number of genes available for commercial sequencing increases and the promise of clinical whole-genome sequencing becomes a reality, the interpretation of the results of these tests becomes more challenging for the practicing neurologist as these studies have the potential to detect novel genetic variants. Such reports are becoming more frequent in general practice, and neurologists are often left to puzzle over the relevance of these ''variants of unknown significance,'' as such genetic changes are often described, and how to communicate this information to the patients and their families. This article will briefly illustrate how clinicians can use such results in the care of their patients. Only genetic variants involving coding sequence will be considered, although similar methods may also be applied to changes such as noncoding alterations or copy number variations. It is also important to note that in some cases, particularly those involving tests that only sequence select exons, negative test results may also require special interpretation. Continuum Lifelong Learning Neurol 2011;17(2):347-352.
Interpretation 1
Although this interpretation may be correct, it does not account for the fact that sequence variants in genes are commonplace and often benign (eg, single nucleotide polymorphisms), even if they lead to an amino acid change. The relative occurrence of polymorphisms can also vary between genes; SETX, for example, has a particularly high frequency of such variants. 5 A closer evaluation of the specific variants may establish their likelihood to be deleterious, but such a determination cannot be established solely by the sequence information provided thus far. It is particularly important to note that AOA2 is autosomal recessive and, by definition, requires mutations in both SETX alleles. The sequencing information as reported does not reveal whether the variants are all present on a single allele or how they may be distributed between the two. Further analysis will be required to determine whether these variants are pathogenic.
Interpretation 2
In contrast to the previous scenario, this interpretation is overly conservative because it does not account for the wealth of publicly available bioinformatics data to aid in assessing these variants. In general, a relatively simple analysis could be quite informative and useful in determining the next steps in the evaluation and management of this patient. In some cases, which may vary depending on the clinician and the practice, this may also be an appropriate stage for a subspecialty consultation.
Interpretation 3
The patient has a suspected hereditary ataxia phenotype consistent with AOA2, as well as coding variants in the SETX gene, which result in changes to the protein; therefore, the variants are likely causative.
Although the patient has a suspected hereditary ataxia consistent with AOA2 and coding variants in SETX, the variants have not been previously described as mutations. Reliably determining whether the variants are causative is therefore not possible.
The patient has a suspected hereditary ataxia consistent with AOA2 and coding variants in SETX, creating a high level of suspicion for this diagnosis. Although the variants in question have not been described previously, a more detailed analysis is warranted as they may be novel disease-causing mutations.
This interpretation is the most appropriate given this scenario but in practice often prompts a subspecialty consultation because many clinicians are unsure about how to approach the required analysis. Fortunately, publicly available resources greatly simplify the steps required to maximize an estimation of the probability that a variant is deleterious. Although many strategies exist, a basic method is outlined here and can be modified depending on the clinical situation and the gene of interest. Several useful online resources can be found at the National Center for Biotechnology Information (NCBI) website (www.ncbi.nlm.nih.gov) and in PracticeT1 Practice Table 1 .
Step 1: Bioinformatics Has the variant previously been reported in normal or diseased individuals? Commercial genetic testing services generally maintain databases of normal and disease-associated variations in the genes they sequence, but the completeness of such databases may vary. Therefore, a variant reported as having ''unknown significance'' may still have been identified previously. Depending on the gene, PRACTICE No published data existed at the time of the initial identification of the variants in this example, nor was a comprehensive gene-specific database for SETX variants available. They could now be identified through a literature review 1, 6, 7 or through the online SETX Variant Database (149.142.212.78/LOVD/home. php?select_db=SETX) 8 (B. Fogel and G. Coppola, unpublished). A search of the dbSNP for human SETX variants identifies only one of the three, p.K992R (rs61742937), as a rare variant found in 1.4% of chromosomes from a sample population of 36 healthy individuals from Utah. No homozygous individuals for the variant were reported, so it cannot be assumed to be benign.
Step 2: Protein Function Is the variant likely to have biological significance? Because of the difficulty in reliably assessing the potential impact of synonymous mutations on gene expression and regulation aside from those that directly disrupt splice sites, only nonsynonymous mutations will be considered here. The simplest method is to utilize an amino acid scoring matrix designed to compare the evolutionary conservation of amino acid substitutions among related proteins. Although several such matrices exist, the two most utilized are the Point Accepted Mutation (PAM) matrix and the Blocks Substitution Matrix (BLOSUM). A detailed description of these matrices and their use 9 is beyond the scope of this discussion. Briefly, PAM matrices are based on percent divergence between two related protein sequences whereas BLOSUM matrices are based on percent similarity. Therefore, for this type of mutational analysis one should choose a low PAM matrix (eg, PAM1) or a high BLOSUM matrix (eg, BLOSUM90). Such an analysis does not account for the relationship of the amino acid residue in question to the entire protein, so a more detailed analysis can be performed using online resources that make predictions based upon the entire protein structure. Such analysis can be strengthened by examining whether the variant lies within a functional domain or whether the original amino acid is conserved phylogenetically across diverse species.
For this example, the p.H435R and p.H2197R changes are less conservative than the p.K992R variant using both PAM1 and BLOSUM90 matrices. A conserved domain search identifies residue 2197 as part of a putative DNA helicase, but the other variants are not within known conserved domains. 1 Detailed analysis using PolyPhen-2 10 and SNPs3D 11 suggests p.K992R is benign whereas both p.H435R and p.H2197R are likely harmful. Phylogenic analysis, again using PolyPhen-2 and SNPs3D, identified lysine (K) as the most common residue at position 992; however, arginine (R) is the naturally observed equivalent residue in the horse (Equus caballus). Histidine (H) was conserved at positions 435 and 2197 in all mammalian species evaluated (including the rhesus macaque, whitetufted-ear marmoset, horse, giant panda, cow, dog, rat, mouse, rabbit, shorttailed gray opossum, and duck-billed platypus), suggesting both residues are likely functionally essential.
Step 3: Heritability Is the variant inherited or did it arise de novo? For an autosomal recessive disorder, are multiple heterozygous variants on separate alleles? For an autosomal dominant disorder, do other affected family members share the same mutation? To answer these questions, additional family members must be available for genetic analysis. It is preferable that the parents of the proband be tested initially because this will most easily address the first two questions. For a suspected dominant mutation, detection in an affected parent or sibling is consistent with causality but is not conclusive. Conversely, detection in an unaffected sibling or parent may suggest the variant is benign but could also reflect incomplete penetrance. Absence in either parent suggests the variant arose de novo (or may reflect alternate paternity). For compound heterozygous variants in suspected autosomal recessive diseases, the variants should segregate between the parents. Failure to do so would not support this mode of inheritance. In some cases it may be cost-effective to contact the company that performed the original testing, as some may offer free testing to parents of the proband to facilitate this analysis.
In this example, genetic testing of the patient's unaffected parents and brother revealed that they were heterozygous for the p.H435R variant (father and brother) and the p.K992R and p.H2197R variants (mother), consistent with the pathogenicity predictions for p.H435R and p.H2197R. Taken together with the available clinical information and the above analysis, the p.H435R and p.H2197R were designated as disease-causing, whereas the p.K992R mutation was suspected to be a benign polymorphism, and the patient was diagnosed with AOA2. 1 These predictions have subsequently been further supported for the p.K992R 6 and p.H2197R 7 variants.
In summary, these steps can be applied to novel genetic variants found in the causative genes for many mendelian disorders to help direct further evaluation and management of patients with suspected neurogenetic disease. It is important to note that predictive analysis should not be utilized as a substitute for expert clinical opinion.
This case illustrates some of the complexities involved in pursuing genetic evaluations, which must always be clearly communicated to the patient and family. This is often beyond the training of most practicing neurologists, and referral to a trained neurogenetics specialist, medical geneticist, or genetic counselor should be considered before initiating the evaluation. This referral is often necessary even for common neurologic diseases; for example, referral for genetic counseling is recommended for patients with rare genetic causes of stroke. 12 Subspecialty referral is also often appropriate for management of the neurogenetic disease in question.
